Leadership & Pay ·
On July 24, 2026, Haemonetics Corporation elected Martin Madaus to its Board of Directors, effective immediately
HAEHaemonetics Corp
On July 24, 2026, Haemonetics Corporation elected Martin Madaus to its Board of Directors, effective immediately. Dr. Madaus, currently a Senior Operating Executive at The Carlyle Group, will serve on the Audit Committee and Governance and Compliance Committee, receiving an annual equity award valued at approximately $200,000. Shareholders also approved amendments to the 2019 Long-Term Incentive Compensation Plan, authorizing 4,680,000 additional shares and extending the plan term through 2036, and extended the 2007 Employee Stock Purchase Plan through 2036. The company operates in the medical technology industry, providing apheresis, blood management, and interventional technologies.